News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Reflect Scientific, Inc. Enters Into Collaborative Relationship With Prominent Cold Chain Development Company


8/16/2011 8:06:35 AM

OREM, UT--(Marketwire - August 16, 2011) - Reflect Scientific, Inc. (OTCBB: RSCF), a provider of diverse products and services for the biotechnology, pharmaceutical and transportation industries, announced that the company will be starting a potentially lucrative relationship with a major player in cold chain development.

"This new collaboration will focus on our passive cooling technologies. Reflect will be developing customer-specific protocols and installing technologies along with developing new techniques that will bring significant improvement to customers' existing products. The Cold Chain Pharmaceuticals industry has been growing in the last few years becoming an $8 billion industry within just the US and worldwide in excess of $400 billion annually. As we have already done with our blast freezing and cryopreservation products, I see a quantum step forward in cold chain management solutions originating from Reflect Scientific," said Dr. Boyd Bowdish, Principal Scientist at Reflect Scientific.

About Reflect Scientific, Inc.
Reflect Scientific, Inc., based in Orem, Utah, develops and markets innovative, proprietary technologies in cryogenic cooling for the biotechnology, pharmaceutical, medical, and transportation markets. Among Reflect Scientific's products are low temperature freezers and refrigerated systems for laboratory, transportation and computer server room uses. For more information, visit www.reflectscientific.com.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.


Contact:

Thomas Tait
Vice President
719-357-5878


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES